Source comparison
Sermorelin Ipamorelin Stack Protocol: Peptide Comparison
Before committing to the sermorelin ipamorelin stack protocol, it's essential to understand how these peptides compare individually and in combination. The table below summarizes receptor mechanism, half-life, typical dosing, and the clinical evidence backing
This comparison does not assign a generated winner or score.
- Before committing to the sermorelin ipamorelin stack protocol, it's essential to understand how these peptides compare individually and in combination. The table below summarizes receptor mechanism, half-life, typical dosing, and the clinical evidence backing each approach.
- Sermorelin
- GHRH receptor (pituitary somatotrophs)
- 8–12 minutes
- 200–500 mcg/injection
- Increases GH pulse amplitude 1.5–2× when combined with GHRP
- Best for researchers prioritizing natural pulse amplification without cortisol/prolactin elevation. Requires co-administration with GHRP for maximum effect
- Ipamorelin
- GHS-R1a (ghrelin receptor)
- ~2 hours
- 200–300 mcg/injection
- Extends pulse duration and prevents somatostatin rebound when paired with GHRH analog
- Cleanest GHRP available. No cortisol or prolactin spike, making it ideal for long-term research protocols where side effect profile matters
- Sermorelin + Ipamorelin Stack
- Dual pathway (GHRH + ghrelin receptors)
- Staggered (8 min + 2 hr)
- 200–300 mcg each, administered within 15–30 min
- Synergistic GH output 2–3× either peptide alone (JCEM data)
- Gold standard for researchers seeking maximum endogenous GH stimulation without exogenous GH administration. Timing and reconstitution discipline required
- CJC-1295 + Ipamorelin
- GHRH receptor (extended) + ghrelin
- ~8 days (CJC) + 2 hr
- CJC 500–1000 mcg weekly, ipamorelin 200–300 mcg daily
- Sustained GHRH tone across 7 days paired with daily ghrelin stimulation
- Alternative for researchers who prefer weekly GHRH dosing. Produces less pulsatile GH pattern and more sustained IGF-1 elevation than sermorelin
- The sermorelin ipamorelin stack protocol outperforms single-peptide approaches specifically because sermorelin's short half-life mimics the body's natural pulsatile GHRH release, while ipamorelin's longer half-life sustains the pulse. This staggered pharmacokinetic profile is closer to physiological GH secretion than extended-release analogs like CJC-1295, which flatten the pulsatile pattern into a sustained elevation. A mechanistically different outcome.